Zhong Sun

Title: Innovations by Zhong Sun in Serine Protease Inhibition

Introduction

Zhong Sun is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of pharmaceutical sciences. He holds a total of 6 patents, focusing primarily on compounds that serve as inhibitors for serine protease enzymes. His work is particularly relevant in the treatment of thrombotic and inflammatory disorders.

Latest Patents

One of Zhong Sun's latest patents involves the development of five-membered heterocycles that are useful as serine protease inhibitors. This invention provides a method for treating thrombotic or inflammatory disorders by administering a therapeutically effective amount of specific compounds. These compounds, defined by their unique formulas, are designed to selectively inhibit serine protease enzymes involved in the coagulation cascade, such as thrombin and factor Xa. The compounds are particularly noted for their selectivity as factor XIa inhibitors, which can be crucial in managing various medical conditions.

Career Highlights

Zhong Sun is currently associated with Bristol-Myers Squibb Company, where he continues to innovate and contribute to the advancement of medical treatments. His expertise in the development of pharmaceutical compositions has made a significant impact in the industry.

Collaborations

Throughout his career, Zhong Sun has collaborated with notable colleagues, including Jon J Hangeland and Mimi Lifen Quan. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic solutions.

Conclusion

Zhong Sun's work in the field of serine protease inhibitors exemplifies the importance of innovation in pharmaceutical sciences. His contributions are paving the way for new treatments that can significantly improve patient outcomes.